2020-2021 SEASONAL INFLUENZA VACCINE INFORMATION FOR IMMUNIZATION PROVIDERS

Office of the Chief Medical Officer of Health
**Table of Contents**

1. What are my accountabilities as an immunization provider? .................................................. 3
2. Who is eligible for publicly funded 2020-2021 seasonal influenza vaccine? .......................... 6
3. What is High-Dose Influenza Vaccine? .................................................................................. 6
4. What are the components of the 2020-2021 seasonal influenza vaccines? ........................ 6
5. What products are being used for the 2020-2021 seasonal influenza? ................................. 7
6. What are the side effects of the seasonal influenza vaccine? ................................................ 7
7. Can the seasonal influenza vaccine cause influenza illness? .................................................. 7
8. Who should NOT routinely be given seasonal influenza vaccine? ........................................ 7
9. Should people who have experienced Ocular Respiratory Syndrome (ORS) following receipt of a previous seasonal influenza vaccine be immunized with the seasonal influenza vaccine? ................................................................. 8
10. Should people who are allergic to eggs receive the seasonal influenza vaccine? ................... 8
11. Should pregnant women receive the seasonal influenza vaccine? ........................................ 8
12. Is seasonal influenza vaccine safe for breastfeeding mothers? ............................................. 8
13. How should the seasonal influenza vaccines be stored? ....................................................... 9
14. How long can a vial of influenza vaccine be used once it is opened? .................................... 9
15. Can I draw up the seasonal influenza vaccine into syringes to be used at a later time? .......... 9
16. How is the seasonal influenza vaccine administered? .......................................................... 9
17. What is the dosage and frequency of the seasonal influenza vaccines? ............................... 9
18. How soon following immunization does protection develop and how long does it last? ........ 10
19. Can you receive seasonal influenza vaccine before or after having donated/received blood or Immune Globulin? ............................................................................................................. 10
20. Can seasonal vaccine, adult pertussis vaccine, and pneumococcal vaccine be given at the same time? ........................................................................................................................................... 10
21. Can seasonal influenza vaccine be administered if other vaccines have been received recently? ................................................................................................................................................. 10
22. Where can I get more information on seasonal influenza vaccine? .................................... 10
23. What is the billing process for practitioners? ..................................................................... 11
The Office of the Chief Medical Officer of Health (OCMOH) monitors influenza activity through its surveillance system year-round; however, the majority of influenza activity occurs between October and April.

For ongoing information on influenza activity, please see our weekly NB flu report which is posted on our website at: http://www2.gnb.ca/content/gnb/en/departments/ocmoh/cdc/content/influenza/influenza_surveillance_activities.html

RESPONSIBILITIES OF ALL IMMUNIZATION PROVIDERS

1. What are my accountabilities as an immunization provider?

All immunization providers of all publicly funded vaccines, including influenza and pneumococcal, shall practice according to the New Brunswick Immunization Program Guide (NBIPG). This includes but is not limited to:

Reporting to Public Health
Adverse Events Following Immunization (AEFI) are to be reported to the local Regional Health Authority (RHA) Public Health as per Policy 2.7 and Standard 3.8 of the New Brunswick Immunization Program Guide and using the New Brunswick AEFI Report Form found at:

https://www2.gnb.ca/content/dam/gnb/Departments/hss/pdf/en/CDC/Epidemiology/NBAEFIFormE.pdf

Recording
Regulation 2009-136, section 14 under the Public Health Act requires that all immunization providers provide the client with a record of immunization. Immunization cards are available at your local RHA Public Health office.

Management of Vaccine/Cold Chain (see Q 13)

Competency
All providers of publicly funded vaccine shall be deemed competent by their employing agency as per Policy 2.4 of the New Brunswick Immunization Program Guide.

Safety
Immunization providers must ensure that:

- Adrenaline is present during vaccine administration.
- Clients are monitored for at least 15 minutes post-immunization.
- The immunization is documented including the lot number of the vaccine. This is important information in the event there is a vaccine recall or an individual experience an adverse event following immunization (AEFI).
Ordering / Receiving Vaccine

New Brunswick’s influenza vaccine is expected to arrive in October. All orders will be reviewed to ensure equitable distribution to all health care providers. Priority groups will be established for supply distribution to ensure that individuals at highest risk receive vaccine first (i.e. hospitals, long-term facilities, etc.).

In the past years, manufacturers supplying Canada with influenza vaccine have experienced shortages or delays in the delivery of their vaccines for various reasons, which are beyond the control of the provinces and territories. To allow for sufficient time to deliver this year’s influenza vaccine to your facility/clinic, **do not schedule your immunization clinics before you have received the vaccine.** Also, New Brunswick receives a percentage of the overall influenza vaccine order for the season in **four or more** shipments over several weeks, so you will **not** receive 100% of your vaccine order in the beginning.

Although vaccination before the onset of the influenza season is strongly preferred (in October or early November), vaccine providers should use every opportunity to give influenza vaccine during the current season, even after influenza activity has been documented in the community (after April).

<table>
<thead>
<tr>
<th>Immunization provider</th>
<th>Where to order influenza vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health care practitioners (physicians, nurse practitioners, and midwives)</td>
<td>Regional Public Health Office</td>
</tr>
<tr>
<td>Licensed nursing homes</td>
<td>Regional Public Health Office</td>
</tr>
<tr>
<td>First Nation health care practitioners and nurses</td>
<td>Central Serum Depot</td>
</tr>
<tr>
<td>Extra Mural Program (EMP)</td>
<td>Central Serum Depot</td>
</tr>
<tr>
<td>All pharmacies including community, hospital, and sub-depots.</td>
<td>Refer to NEW Influenza Vaccine Ordering Process for Pharmacies below</td>
</tr>
</tbody>
</table>

Regional Public Health will only release vaccine to immunization providers who bring insulated containers large enough to hold vaccine, ice/gel pack, insulating materials, and temperature monitoring devices (min-max thermometers).

First Nations and EMP who provide influenza vaccine must order directly through Central Serum Depot using the Publicly Funded Vaccines / Biologics Order Form. Please specify the date of delivery on the form and confirm whether Canada Post delivers to your location to ensure vaccine will be delivered safely. [https://www2.gnb.ca/content/dam/gnb/Departments/hs/pdf/en/CDC/HealthProfessionals/11954e4-1-5_Public-Funded-Vaccine-letter%20size-interactive.pdf](https://www2.gnb.ca/content/dam/gnb/Departments/hs/pdf/en/CDC/HealthProfessionals/11954e4-1-5_Public-Funded-Vaccine-letter%20size-interactive.pdf)

For the 2020-2021 influenza season, vaccination services for residents of adult residential facilities (ARF) are being planned to include the New Brunswick Extramural Program working in collaboration with other partners. Providers will access Fluzone® High-Dose vaccine directly through Central Serum Depot using the Publicly Funded Vaccines / Biologics Order Form. Please specify the name of the ARF in comments on the order form.
NEW Influenza Vaccine Ordering Process for Pharmacies

New Brunswick’s influenza vaccine is expected to arrive in October. All orders will be reviewed to ensure equitable distribution to all health care providers. Priority groups will be established for supply distribution to ensure that individuals at highest risk receive vaccine first (i.e. hospitals, long-term facilities, etc.)

In the past years, manufacturers supplying Canada with influenza vaccine have experienced shortages or delays in the delivery of their vaccines for various reasons, which are beyond the control of the provinces and territories. To allow for sufficient time to deliver this year’s influenza vaccine to your facility/clinic, **do not schedule your immunization clinics before you have received the vaccine.** Also, New Brunswick receives a percentage of the overall influenza vaccine order for the season in four or more shipments over several weeks, so you will **not** receive 100% of your vaccine order in the beginning.

<table>
<thead>
<tr>
<th>Distribution Group</th>
<th>Ordering Process</th>
<th>Comments</th>
</tr>
</thead>
</table>
| Hospital pharmacies (including designated sub-depots) | - Place vaccine orders for patients and staff with McKesson Canada on Pharmaclik using the McKesson Item Number.  
- **McKesson will communicate the details of the promotion to the customers through Pharmaclik in mid-August.**  
- Each unit contains 10 doses (see product information below) | - Effective October 1, 2020 the Department of Health will no longer be invoicing the Regional Health Authorities for influenza used for their staff immunization.  
- Designated hospital sub-depots no longer use the Public Health Information Solution (PHIS) to order influenza vaccine. |
| Community pharmacies (including designated sub-depots and excluding Shoppers Drug Mart) | - Place vaccine orders with McKesson Canada on Pharmaclik using the McKesson Item Number.  
- **McKesson will communicate the details of the promotion to the customers through Pharmaclik in mid-August.**  
- Each unit contains 10 doses (see product information below) | - Designated community sub-depots no longer use the Public Health Information Solution (PHIS) to order influenza vaccine.  
- For assistance or questions please call 1-800-565-7821 to speak to a McKesson Customer Service Specialist. |
| Shoppers Drug Mart pharmacies | - Place vaccine orders with the Matrix Distribution. Centre using the DIN  
- Each unit contains 10 doses (see product information below) | - Additional specific ordering instructions will be provided by Shoppers Drug Mart closer to order dates. |

**Note:** If you have already submitted your order to Central Serum Depot, you will need place your order as per the above process.
Product Information for Pharmacies ordering from McKesson:

<table>
<thead>
<tr>
<th>Supplier</th>
<th>Product name</th>
<th>Product Number</th>
<th>McKesson Item Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sanofi Pasteur</td>
<td>Fluzone (Multidose vial)</td>
<td>136181</td>
<td>153899 – generic item# which will substitute to available product.</td>
</tr>
<tr>
<td>Sanofi Pasteur</td>
<td>Fluzone (Prefilled syringe)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GSK</td>
<td>FluLaval Tetra (Multidose vial)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Product Information for pharmacies ordering from Matrix (Shoppers Drug Mart)

<table>
<thead>
<tr>
<th>Supplier</th>
<th>Product name</th>
<th>DIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sanofi Pasteur</td>
<td>Fluzone (Multidose vial)</td>
<td>2432730</td>
</tr>
<tr>
<td>Sanofi Pasteur</td>
<td>Fluzone (Prefilled syringe)</td>
<td>2420643</td>
</tr>
<tr>
<td>GSK</td>
<td>FluLaval Tetra (Multidose vial)</td>
<td>2420783</td>
</tr>
</tbody>
</table>

**ELIGIBILITY**

2. **Who is eligible for publicly funded 2020-2021 seasonal influenza vaccine?**

- A universal influenza vaccine program will be publicly funded for all New Brunswick residents. Quadrivalent influenza vaccine will be offered to individuals age 6 months and older including residents of long-term care facilities who are under the age of 65 years at no cost to the recipients.

- Fluzone® High-Dose vaccine will be offered to residents aged 65 years and older living in long-term care facilities (licensed nursing homes and adult residential facilities) at no cost to the recipients.

   For more information please check the website at: [www.gnb.ca/flu](http://www.gnb.ca/flu)

**2020-2021 VACCINE COMPONENTS/PRODUCTS**

3. **What is High-Dose Influenza Vaccine?**

Fluzone High-Dose is a three-component (trivalent) inactivated influenza vaccine that is licensed specifically, for people 65 years and older. The High-Dose vaccine contains four times the antigen of standard-dose inactivated influenza vaccines which is intended to give older people a stronger immune response (i.e., higher antibody levels), and therefore, better protection against influenza.

4. **What are the components of the 2020-2021 seasonal influenza vaccines?**

It is recommended that quadrivalent vaccines for use in the 2020 - 2021 northern hemisphere influenza season contain the following:

**Egg-based vaccines**
• an A/Guangdong-Maonan/SWL1536/2019 (H1N1) pdm09-like virus;
• an A/Hong Kong/2671/2019 (H3N2)-like virus;
• a B/Washington/02/2019 (B/Victoria lineage)-like virus; and
• a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

It is recommended that trivalent influenza vaccines for use in the 2020 - 2021 northern hemisphere influenza season contain the following:

Egg-based Vaccines
• an A/Guangdong-Maonan/SWL1536/2019 (H1N1) pdm09-like virus;
• an A/Hong Kong/2671/2019 (H3N2)-like virus; and
• a B/Washington/02/2019 (B/Victoria lineage)-like virus.

5. What products are being used for the 2020-2021 seasonal influenza?

- Flulaval® Tetra (GSK)
- Fluzone® Quadrivalent (Sanofi)
- Fluzone® High-Dose (Sanofi)

Flulaval® Tetra and Fluzone® Quadrivalent are supplied in 10 dose vials. A small quantity of Fluzone® Quadrivalent single use pre-filled syringes will be available. Fluzone® High-Dose Quadrivalent is supplied in pre-filled syringes.

SIDE EFFECTS/CONTRAINDICATIONS

6. What are the side effects of the seasonal influenza vaccine?

One third of those immunized report soreness at the injection site for up to two days. Flu-like symptoms (fever, sore muscles, and tiredness) may occur within 6 to 12 hours after immunization and last 1 to 2 days, especially in those receiving the vaccine for the first time. Anaphylactic hypersensitivity reactions occur rarely.

7. Can the seasonal influenza vaccine cause influenza illness?

The seasonal influenza vaccine does not contain live virus and therefore cannot cause influenza.

8. Who should NOT routinely be given seasonal influenza vaccine?

The following people should not routinely receive seasonal influenza vaccine:
• Infants less than 6 months of age;
• People who have had a serious allergic reaction (anaphylaxis) to any of the components of influenza vaccine (with the exception of egg);
• People who have a serious acute febrile illness;
• People known to have had Guillain-Barré Syndrome (GBS) within 6 weeks of a previous influenza vaccine. It is not known whether influenza vaccination is causally associated with increased risk of recurrent GBS in persons with a previous history of GBS due to any cause. Avoiding subsequent influenza vaccination of persons known to have had GBS within six weeks of a previous influenza vaccination appears prudent at this time.
9. Should people who have experienced Ocular Respiratory Syndrome (ORS) following receipt of a previous seasonal influenza vaccine be immunized with the seasonal influenza vaccine?

Oculo-respiratory syndrome (ORS), which is defined as the presence of bilateral red eyes and one or more associated symptoms (cough, wheeze, chest tightness, difficulty breathing, difficulty swallowing, hoarseness, or sore throat) that starts within 24 hours of vaccination, with or without facial edema, was found during the 2000–2001 influenza season; few cases have been reported since then. ORS is not considered to be an allergic response.

There is no evidence to suggest that oculo-respiratory syndrome (ORS) will be a concern following immunization. Individuals who have experienced ORS, including those with a severe presentation (bilateral red eyes, cough, sore throat, hoarseness, facial swelling) but without lower respiratory tract symptoms, may be safely re-immunized with influenza vaccine.

Persons who experienced ORS with lower respiratory tract symptoms (wheeze, chest tightness, difficulty breathing) within 24 hours of immunization, an apparent significant allergic reaction to the immunization or any other symptoms (throat constriction, difficulty swallowing) that raise concerns regarding the safety of re-immunization should have a consultation with a Medical Officer of Health or another expert.

10. Should people who are allergic to eggs receive the seasonal influenza vaccine?

All influenza vaccine products authorized for use in Canada are manufactured by a process involving chicken eggs, which may result in the vaccines containing trace amounts of residual egg protein. NACI has concluded that egg allergic individuals without other contraindications may be vaccinated against influenza (with any product) without a prior influenza vaccine skin test and with the full dose. The vaccine may be given in any settings where vaccines are routinely administered. As with any vaccine, immunizers should be prepared for and have the necessary equipment to respond to a vaccine emergency at all times. For further information please see the Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2020-2021.

11. Should pregnant women receive the seasonal influenza vaccine?

All pregnant women should receive seasonal influenza immunization, as evidence demonstrates they are at higher risk of complications from influenza.

12. Is seasonal influenza vaccine safe for breastfeeding mothers?

Seasonal influenza vaccine is safe for breastfeeding mothers.
VACCINE STORAGE/ADMINISTRATION

13. How should the seasonal influenza vaccines be stored?

- Influenza vaccine must be stored between 2° - 8° at all times.
- The vaccine should not be frozen and must be protected from light.
- If vaccine is exposed to an adverse storage condition please contact the manufacturer first for instructions.
- Any unused/outdated vaccine is to be returned to CSD, McKesson Canada, or Matrix Distribution Centre.
- Attention must be paid to the duration of stability of vaccine once it has been opened.

14. How long can a vial of influenza vaccine be used once it is opened?

- An opened vial of Flulaval Tetra must be used within 28 days from the date it was opened.
- A multidose vial of Fluzone® or FLUZONE® High-Dose which has been entered and stored at 2° to 8°C may be used up to the expiry date indicated on the vial label.

15. Can I draw up the seasonal influenza vaccine into syringes to be used at a later time?

The manufacturer has no data to confirm that immunogenicity of the product will be preserved after prolonged exposure to the plastic of the syringe. The company also has concerns regarding bacterial contamination. Therefore, influenza vaccine should be injected as soon as possible after being drawn up.

16. How is the seasonal influenza vaccine administered?

- The seasonal influenza vaccine is administered intramuscularly.
- The deltoid muscle is the recommended site in adults/older children (> 1 year old).
- The anterolateral thigh is the recommended site in infants (< 1 year old)

DOSAGE

17. What is the dosage and frequency of the seasonal influenza vaccines?

For intramuscular quadrivalent influenza vaccine (QIV), the dose is 0.5 ml for all age groups.

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Dose</th>
<th>No. of Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>9 years and older</td>
<td>0.5 ml</td>
<td>1</td>
</tr>
<tr>
<td>6 months-8 years*</td>
<td>0.5 ml</td>
<td>1 or 2*</td>
</tr>
</tbody>
</table>

* Children 6 months to less than 9 years of age who have never received the seasonal influenza vaccine require two doses of influenza vaccine, with a minimum interval of four weeks between doses. Eligible children <9 years of age who have received one or more doses of seasonal influenza vaccine in the past should receive one dose per season thereafter.
IMMUNOGENICITY AND EFFICACY

18. How soon following immunization does protection develop and how long does it last?

Protection from the seasonal influenza vaccine generally begins 10 to 14 days after immunization and may last 6 months or longer.

SIMULTANEOUS ADMINISTRATION OF OTHER VACCINES

19. Can you receive seasonal influenza vaccine before or after having donated/received blood or Immune Globulin?

Yes.

20. Can seasonal vaccine, adult pertussis vaccine, and pneumococcal vaccine be given at the same time?

Yes, they can be administered at the same time but they should be administered via separate syringes in different sites. Pneumococcal immunization is recommended once in a lifetime, except in certain high-risk individuals as specified in the Canadian Immunization Guide. Pertussis vaccine is recommended in childhood and adolescence, once as an adult, and during every pregnancy ideally between 27 and 32 weeks of gestation.

21. Can seasonal influenza vaccine be administered if other vaccines have been received recently?

You can administer seasonal influenza vaccine if other vaccines have been received recently. There is no interval of time needed between receiving seasonal influenza vaccine and any other vaccines.

MORE INFORMATION

22. Where can I get more information on seasonal influenza vaccine?

For more information on influenza vaccine, contact your local Public Health office. You may also check the following references:

- Canadian Public Health Association: http://www.immunize.ca;
23. What is the billing process for practitioners?

- Physicians and Nurse Practitioners are to refer to the Physicians Manual for billing practices specific to 2020-2021 seasonal influenza immunization.
- Midwives are to refer to the Midwives’ Medicare Billing Manual.
- Pharmacist claims are submitted as required under the New Brunswick Prescription Drug Program (NBPDP) Plan “I”

24. What guidelines do I need to follow during COVID-19?

- See the attached New Brunswick Guidance for Influenza Vaccine Delivery in the Presence of COVID-19 developed by the Public Health Agency of Canada (PHAC) in consultation with the Canadian Immunization Committee and the National Advisory Committee on Immunization (NACI) and adapted for the province of New Brunswick.
- Public Health Agency of Canada’s "Guidance for Influenza Vaccine Delivery in the Presence of COVID-19" is now available online.